Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dexmethylphenidate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Dexmethylphenidate HCl extended-release capsules | DRUG | - |
Inclusion Criteria: * Children 6 - 12 with a diagnosis of ADHD of any type , Same teacher who is willing to complete the assessment during the school term Exclusion Criteria: * Previous cardiac problems of the patient or the parents or current cardiac findings of the patient; Relevant medical con...
Dexmethylphenidate is used for the treatment of attention-deficit/hyperactivity disorder (ADHD) and attention deficit disorder (ADD) in children. It is a small molecule being developed by Novartis AG for these psychiatric conditions.
Dexmethylphenidate is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
Dexmethylphenidate is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 3 trial has been completed.
Dexmethylphenidate has one completed Phase 3 trial, NCT00301236, titled "Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder." The trial enrolled 252 participants in the United States.
Dexmethylphenidate is the drug name, and the clinical trial refers to it as dexmethylphenidate HCl, which stands for dexmethylphenidate hydrochloride. These names refer to the same compound.